Bachem Holding BANB.SW
SwitzerlandHealthcare · BiotechnologySIX Swiss Exchange · CHF
84.30 CHF (+4.8%)
10 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Bachem Holding AG is a Swiss biotechnology company that manufactures peptides and oligonucleotides for the pharmaceutical and biotechnology industry, acting as a supplier of active ingredients and development services for medicines.
Listed on SIX Swiss Exchange · Symbol BANB.SW · SWX: BANB · Currency CHF
Key points
from its scores- ✓Good share-price trend7.5
- ✓Very solid balance sheet7.3
- ✕Little competitive advantage3.3
- ✕Demanding valuation3.3
- ✕Weak growth4.9
AI analysis
bottom line, main risk, context and newsThe solid financial position and positive momentum do not offset weak free cash flow generation and elevated valuation.
Bachem shows solid financial health (ND/EBITDA 0.74) and strong momentum (38.32% over 12 months), but its valuation is demanding (P/E 40.63) and cash conversion is very negative (-98.44%), which weighs on quality and cash flow attractiveness.
The extremely negative free cash flow conversion (-98.44%) indicates that current growth is not translating into cash, a key operational risk for a company with a high valuation.
Context and risks
Swiss biotech company with moderate regulatory exposure. The country's governance risk is applied as a base penalty, with no additional specific aggravating factors identified in this run.
Is Bachem Holding stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 78% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 40.6 | 26.7 | +52% |
| EV / EBITDA | 29.4 | 14.5 | +103% |
| Price / book | 4.2 | 4.1 | +2% |
| Price / sales | 8.5 | 3.4 | +149% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 84.30 CHF, +4.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 4.9 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 40.6
- Forward P/E
- 26.1
- EV / EBITDA
- 29.4
- Price / book
- 4.2
- Price / sales
- 8.5
- PEG
- 0.61
- Market cap
- 6.0B CHF
- Enterprise value
- 6.2B CHF
Profitability
- ROE
- 10.6%
- ROA
- 4.5%
- ROIC (approx.)
- 7.1%
- Gross margin
- 27.0%
- Operating margin
- 16.6%
- Net margin
- 21.0%
- Free cash flow
- −207.2M CHF
- FCF yield
- −3.4%
- Cash conversion
- −98%
Solvency
- Total debt
- 208.1M CHF
- Net debt
- 156.5M CHF
- Cash
- 51.6M CHF
- EBITDA
- 210.4M CHF
- Net debt / EBITDA
- 0.74
- Debt / equity
- 14.41
- Current ratio
- 1.60
- Quick ratio
- 0.46
Growth
- Revenue growth
- +4.3%
- Earnings growth
- +0.0%
- EPS (TTM)
- 1.98 CHF
- EPS (forward)
- 3.08 CHF
Dividend
- Dividend yield
- 1.1%
- Payout
- 45.5%
Risk and market
- Beta
- 0.79
- Analyst consensus
- none (10)
- Target price
- 84.30 CHF
- 52-week range
- 48.52 – 84.10
Recent news
All BANB.SW news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Bachem Holding
Is Bachem Holding stock cheap or expensive?
On P/E and EV / EBITDA, it trades 78% above the Healthcare median on average. Valuation score: 3.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 84.30 CHF, +4.8% versus the price. This is not investment advice.
What score does Bachem Holding get on MeridIAn Screener?
It scores 5.1 out of 10, rank 1,629 of 2,130 (better than 21% of the companies analysed). Its strongest category is Momentum (7.5) and its weakest, Quality / Moat (3.3). Analysis of 08/10/2026.
What is Bachem Holding's P/E ratio?
Its P/E is 40.6: the share price equals 40.6 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 26.1.
How much is Bachem Holding worth on the stock market?
Its market capitalisation is 6.0B CHF and its enterprise value, debt included, is 6.2B CHF.
How much debt does Bachem Holding have?
Its net debt (debt minus cash) is 156.5M CHF. That is 0.74 times its EBITDA; the Healthcare median is 1.53.
Does Bachem Holding pay a dividend?
Yes: its dividend yield is 1.12% and it pays out 45% of its earnings.
How has Bachem Holding stock performed over the last year?
It has risen 44.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 48.52 and 84.10 CHF. Past performance does not guarantee future results.
What do analysts think of Bachem Holding?
10 analysts cover it; their average recommendation is “none” and their average target is 84.30 CHF (+4.8% versus the price). It is an estimate, not market data.